Rising prevalence of eye infections worldwide is propelling the growth of conjunctivitis market. Increasing awareness about eye health and advancements in medical treatments are also driving market growth. Additionally, the growing geriatric population and increasing demand for over-the-counter medications are contributing to the expansion of the conjunctivitis market.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Type, Patients Type, Drug Class |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Atopix Therapeutics., Allegran, Ocular Therapeutix,, Santen Pharmaceutical Co.., Novartis, Boehringer Ingelheim, Pfizer Inc, Allegran, Sun Pharma, Sirion Therapeutics, |
However, high cost associated with prescription medications and lack of access to proper healthcare facilities in developing regions are major restraints hindering the growth of conjunctivitis market. Moreover, strict regulatory guidelines and limited availability of effective treatment options are posing challenges for market players in the conjunctivitis market.